<DOC>
	<DOCNO>NCT01842672</DOCNO>
	<brief_summary>The combination mitoxantrone clofarabine reinduction therapy safe , well tolerate effective child , adolescent young adult poor risk refractory/relapsed acute leukemia high grade non-Hodgkin lymphoma ( NHL ) .</brief_summary>
	<brief_title>Mitoxantrone Clofarabine Treatment Recurrent NHL Acute Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Age ≤30.99 year old Disease Status ( Part A Safety Phase ) ALL 1st , 2nd 3rd relapse OR primary induction failure . AML 1st ,2nd 3rd relapse OR primary induction failure . Tor B Lymphoblastic Lymphoma ( TLBL , BLBL ) ; Diffuse Large Bcell Lymphoma ( DLBCL ) Burkitt Lymphoma/Leukemia 1st , 2nd 3rd relapse OR primary induction failure . 5.1.2.2 ( Part B Efficacy Phase ) ALL 2nd 3rd relapse OR primary induction failure . AML 2nd 3rd relapse OR primary induction failure . Tor B Lymphoblastic Lymphoma ( TLBL , BLBL ) ; Diffuse Large Bcell Lymphoma ( DLBCL ) Burkitt Lymphoma/Leukemia 1st , 2nd 3rd relapse OR primary induction failure . Adequate renal function define : Normal Serum creatinine base age Creatinine clearance &gt; 60 ml/min &gt; 60 ml/min/1.73 m2 equivalent radioisotope glomerular filtration rate ( GFR ) determine institutional normal range . Adequate liver function define : Direct bilirubin &lt; 1.5 upper limit normal ( ULN ) age , SGOT ( AST ) SGPT ( ALT ) &lt; 3 x ULN Adequate cardiac function define : Shortening fraction &gt; 27 % echocardiogram , Ejection fraction &gt; 50 % radionuclide angiogram echocardiogram . Performance Status For patient age 116 year , Lansky score ≥60 . For patient &gt; 16 year , Karnofsky score ≥60 . Negative urine pregnancy test females child bear age . Prior Therapy Patients eligible treated clofarabine , mitoxantrone , combination past . However , maximal lifetime cumulative previous anthracycline dose exceed doxorubicin dose equivalent 450 mg/m2 ( see Table 1 ) . Patients receive one anthracycline prior study entry individual agent cumulative dose convert doxorubicin equivalent add together ( eg , patient receive cumulative dose Daunorubicin 200 mg/m2 Mitoxantrone 48 mg/m2 total doxorubicin dose equivalent 358.6 mg/m2 ( 200 mg/m2 x 0.833 + 48 mg/m2 x 4 ) . Table 1 . Anthracycline Conversion Agent Conversion Factor Doxorubicin Dose Doxorubicin Multiply total dose x 1 Daunorubicin Multiply total dose x 0.833 Idarubicin Multiply total dose x 5 Mitoxantrone Multiply total dose x 4 Informed Consent Patients patient 's legally authorized guardian must fully inform illness investigational nature protocol ( include foreseeable risk possible side effect ) , must sign informed consent accordance institutional policy approve U.S. Department Health Human Services . Patients prior myeloablative allogeneic stem cell transplantation &lt; 3 month prior propose enrollment study and/or ≥Grade II active acute GVHD extensive chronic GVHD . Females pregnant ( positive HCG ) lactating . Karnofsky &lt; 60 % Lansky &lt; 60 % less 16 year age . Age &gt; 30.99 year age . Patients active CNS disease . Any patient uncontrolled infection prior study entry . Patients Down syndrome exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>pediatric non-hodgkins lymphoma</keyword>
	<keyword>pediatric acute leukemia</keyword>
	<keyword>clofarabine</keyword>
	<keyword>mitoxantrone</keyword>
</DOC>